You are here

  • Home
  • Archive
  • Volume 17, Issue 6
  • Low-molecular-weight heparin prophylaxis does not affect mortality in acutely ill medical patients at low risk for venous thromboembolism

Article Text

Article menu
Download PDFPDF
Electronic pages
Low-molecular-weight heparin prophylaxis does not affect mortality in acutely ill medical patients at low risk for venous thromboembolism
  1. Anders Själander
  1. Department of Public Health and Clinical Medicine, Umeå University. SE 90185 Umeå, Sweden
  1. Correspondence to: Anders Själander
    Department of, Public Health and Clinical Medicine, Umeå University, Umeå 90185 Sweden; Anders.Sjalander{at}medicine.umu.se

https://doi.org/10.1136/ebmed-2012-100631

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Kakkar AK, Cimminiello C, Goldhaber SZ, et al. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med 2011; 365: 2463– 72.OpenUrlCrossRefPubMedWeb of Science

    Context

    Pharmacological thromboprophylaxis has been proven effective for preventing venous thromboembolic events (VTE) in both surgical and acutely ill medical patients.1,–,3 Even though clinical guidelines recommend its use in both patient populations, thromboprophylaxis is more frequently used in surgical patients.4 This could be due to a lack of evidence for a mortality reduction associated with pharmacological thromboprophylaxis in acutely ill medical patients, even when data are pooled together in a meta-analysis.5

    Methods

    This study is an international multi-centre double-blind, placebo-controlled, randomised trial comparing enoxaparin 40 mg daily for 10±4 days compared with placebo …

    View Full Text

    Footnotes

    • Competing interests AS has received lecturing fees, travel support and consultancy fees from Actelion, Bayer, Bristol Myer Squibb, Boehringer Ingelheim, CSL Behring, Novartis, Octapharma, Pfizer and Sanofi Aventis.